/wp-content/uploads/2018/01/BSM_logo.png00keymaster/wp-content/uploads/2018/01/BSM_logo.pngkeymaster2014-05-20 18:02:262018-01-06 18:02:45Avita Medical appoints new Chairman
Link here. Highlights · Clinical study interim results demonstrate ReCell® superiority as treatment for hypopigmentation. · Statistically significant pigment restored in patients’ hypopigmented scars treated with ReCell. · Results support the Company’s commercial strategy for use of ReCell in aesthetic plastic surgery. · Study results delivered at key European conferences, enhancing ReCell industry profile. Northridge, Calif., […]
/wp-content/uploads/2018/01/BSM_logo.png00keymaster/wp-content/uploads/2018/01/BSM_logo.pngkeymaster2014-05-15 18:02:552018-01-06 18:03:30ReCell® Spray-on Skin® demonstrates superior results treating hypopigmentation in aesthetic plastic surgery trial
May 2, 2014. Link here. Company to be admitted to AIM with a market capitalisation of £25.7 million Union MedTech plc today announces it is to be admitted to the AIM market of the London Stock Exchange with a market capitalisation of £25.7 million. On Admission, the acquisition by Union MedTech of REX Bionics Limited (“REX […]
/wp-content/uploads/2018/01/BSM_logo.png00keymaster/wp-content/uploads/2018/01/BSM_logo.pngkeymaster2014-05-02 18:03:372018-01-06 18:04:31Union MedTech plc raises £10 million to commercialise and develop REX, a hands-free robotic exoskeleton
NEXVET ANNOUNCES US$31.5 MILLION FINANCING U.S. Institutional Investors Lead Oversubscribed Round To Advance Monoclonal Antibody Clinical Programs For Companion Animal Health MELBOURNE, Australia–April 16, 2014 –Nexvet Biopharma, a leading veterinary biologic drug developer, today announced the closing of its US$31.5 million Series B round of financing. Top–‐tier U.S.–‐based institutional investors Farallon Capital Management, LLC, Adage […]
/wp-content/uploads/2018/01/BSM_logo.png00keymaster/wp-content/uploads/2018/01/BSM_logo.pngkeymaster2014-04-10 18:06:172018-01-06 18:06:35Avita Medical – ReCell receives FDA IDE Compassionate use approval.
Australia, 8 April 2014 – Link here. NORTHRIDGE, Calif., and CAMBRIDGE, United Kingdom, 8 April 2014 – Regenerative medicine company Avita Medical Limited “Avita Medical” (ASX:AVH), (OTCQX:AVMXY) is pleased to advise that it has developed and released to market a new version of ReCell® ‘Spray‐on Skin®’ that no longer requires refrigeration. This greatly improves the commercial and […]
/wp-content/uploads/2018/01/BSM_logo.png00keymaster/wp-content/uploads/2018/01/BSM_logo.pngkeymaster2014-04-08 17:54:172018-01-06 17:54:40Avita Medical – ReCell containing ambient-stored enzyme launched in United Kingdom and europe
Link here. BIRMINGHAM, United Kingdom –‐ April 3, 2014 – Nexvet Biopharma, a leading veterinary biologic drug developer, today announced that its Chief Scientific Officer, Professor David Gearing, will be presenting at the British Small Animal Veterinary Association (BSAVA) Congress 2014. The BSAVA Congress runs from April 3 – 6 and is one of Europe’s largest […]
/wp-content/uploads/2018/01/BSM_logo.png00keymaster/wp-content/uploads/2018/01/BSM_logo.pngkeymaster2014-04-03 18:05:422018-01-06 18:06:04Nexvet shares promise of new treatments for chronic illness in companion animals with BSAVA Congress 2014
SEA:NZX MARKET UPDATE 1 April 2014 SeaDragon Investor Update March 2014 (Link here). SeaDragon, Australasia’s largest refiner and blender of high-quality, internationally certified concentrated fish oils and fractions, including Omega-3 oils, today releases its investor update. The update includes: • an update on trading; • significant growth in squalene business following the execution of a raw […]
10 March 2014. Link here. SeaDragon signs significant raw material supply contract Agreement overcomes historical supply constraints Australasia’s largest fish-oil refiner SeaDragon (NZX: SEA) announces a new raw material supply agreement has been signed that will underpin its Nelson-based squalene manufacturing operations, and enable the business to seek new market opportunities in the pharmaceutical and cosmetic […]
/wp-content/uploads/2018/01/BSM_logo.png00keymaster/wp-content/uploads/2018/01/BSM_logo.pngkeymaster2014-03-10 17:56:362018-01-06 17:56:55SeaDragon signs significant raw material supply contract
/wp-content/uploads/2018/01/BSM_logo.png00keymaster/wp-content/uploads/2018/01/BSM_logo.pngkeymaster2014-02-28 17:56:122018-01-06 17:56:27Avita Medical December 2013 Half Year Report
Avita Medical appoints new Chairman
/in Avita Medical, Portfolio CompaniesAustralia, 20 May 2014. Link here. Read more about Avita Medical appoints new Chairman
ReCell® Spray-on Skin® demonstrates superior results treating hypopigmentation in aesthetic plastic surgery trial
/in Avita Medical, Portfolio CompaniesLink here. Highlights · Clinical study interim results demonstrate ReCell® superiority as treatment for hypopigmentation. · Statistically significant pigment restored in patients’ hypopigmented scars treated with ReCell. · Results support the Company’s commercial strategy for use of ReCell in aesthetic plastic surgery. · Study results delivered at key European conferences, enhancing ReCell industry profile. Northridge, Calif., […]
Union MedTech plc raises £10 million to commercialise and develop REX, a hands-free robotic exoskeleton
/in Portfolio Companies, Rex BionicsMay 2, 2014. Link here. Company to be admitted to AIM with a market capitalisation of £25.7 million Union MedTech plc today announces it is to be admitted to the AIM market of the London Stock Exchange with a market capitalisation of £25.7 million. On Admission, the acquisition by Union MedTech of REX Bionics Limited (“REX […]
NEXVET ANNOUNCES US$31.5 MILLION FINANCING
/in Pharmamark, Portfolio CompaniesNEXVET ANNOUNCES US$31.5 MILLION FINANCING U.S. Institutional Investors Lead Oversubscribed Round To Advance Monoclonal Antibody Clinical Programs For Companion Animal Health MELBOURNE, Australia–April 16, 2014 –Nexvet Biopharma, a leading veterinary biologic drug developer, today announced the closing of its US$31.5 million Series B round of financing. Top–‐tier U.S.–‐based institutional investors Farallon Capital Management, LLC, Adage […]
Avita Medical – ReCell receives FDA IDE Compassionate use approval.
/in Avita Medical, Portfolio CompaniesASX release here.
Avita Medical – ReCell containing ambient-stored enzyme launched in United Kingdom and europe
/in Avita Medical, Portfolio CompaniesAustralia, 8 April 2014 – Link here. NORTHRIDGE, Calif., and CAMBRIDGE, United Kingdom, 8 April 2014 – Regenerative medicine company Avita Medical Limited “Avita Medical” (ASX:AVH), (OTCQX:AVMXY) is pleased to advise that it has developed and released to market a new version of ReCell® ‘Spray‐on Skin®’ that no longer requires refrigeration. This greatly improves the commercial and […]
Nexvet shares promise of new treatments for chronic illness in companion animals with BSAVA Congress 2014
/in Pharmamark, Portfolio CompaniesLink here. BIRMINGHAM, United Kingdom –‐ April 3, 2014 – Nexvet Biopharma, a leading veterinary biologic drug developer, today announced that its Chief Scientific Officer, Professor David Gearing, will be presenting at the British Small Animal Veterinary Association (BSAVA) Congress 2014. The BSAVA Congress runs from April 3 – 6 and is one of Europe’s largest […]
SeaDragon Investor Update March 2014
/in Portfolio Companies, SeaDragonSEA:NZX MARKET UPDATE 1 April 2014 SeaDragon Investor Update March 2014 (Link here). SeaDragon, Australasia’s largest refiner and blender of high-quality, internationally certified concentrated fish oils and fractions, including Omega-3 oils, today releases its investor update. The update includes: • an update on trading; • significant growth in squalene business following the execution of a raw […]
SeaDragon signs significant raw material supply contract
/in Portfolio Companies, SeaDragon10 March 2014. Link here. SeaDragon signs significant raw material supply contract Agreement overcomes historical supply constraints Australasia’s largest fish-oil refiner SeaDragon (NZX: SEA) announces a new raw material supply agreement has been signed that will underpin its Nelson-based squalene manufacturing operations, and enable the business to seek new market opportunities in the pharmaceutical and cosmetic […]
Avita Medical December 2013 Half Year Report
/in Avita Medical, Portfolio CompaniesASX Announcement (link here). 28 February 2014.